Psilocybin-Assisted Psychotherapy: Tryp Therapeutics Sees Promising Interim Results in Phase II Clinical Trial for Binge Eating Disorder!

Psilocybin-assisted psychotherapy appears to be a promising treatment approach for Binge Eating Disorder, with preliminary research showing encouraging results. By combining the power of psychedelic-assisted psychotherapy with an evidence-based approach to treating BED, this treatment could provide a powerful tool in helping those struggling with BED to overcome their disorder.

TRP-8802 has been shown to provide significant and lasting improvement in primary endpoints for all five patients, with an average daily reduction in binge eating episodes of 80.4%. Moreover, Hospital Anxiety and Depression Scale (HADS) anxiety and depression scores showed improvement in relation to patients’ baseline levels. The drug was also found to be safe and well tolerated by all participants.

Tryp Therapeutics, Inc. (CSE:TRYP) (OTCQB:TRYPF) has released encouraging interim results from their Phase II STOP trial, which is examining the use of TRP-8802 (oral psilocybin) and psychotherapy to treat Binge Eating Disorder (BED). After dosing the first five patients, the results have been promising and mark the first time that psilocybin has been used in conjunction with psychotherapy as a therapeutic intervention in BED patients. With the help of the University of Florida, Tryp is leading the way in exploring the potential of psilocybin to treat diseases with high unmet medical needs.

The first patient in the STOP trial has seen remarkable results following the post-dosing integration session with the trial’s psychotherapists. In only a four-week period, anxiety was reduced overall, anxiety around food was decreased, compulsive overeating was reduced, and self-image and confidence were improved. After analyzing the results of the additional four patients, the same remarkable results have been seen. Binge eating behavior was significantly reduced for all patients, as measured in multiple assessments of efficacy which the FDA had already approved prior to the study’s commencement.

Reductions in Binge Eating Episodes

  • Patients reported a remarkable reduction in daily binge eating episodes by an average of over 80% during the four-week post-dosing measurement period. Everyone experienced at least a 60% decrease in binge eating episodes, demonstrating the strength of this treatment.
  • Four out of five patients experienced a dramatic reduction in daily binge eating episodes during the four-week post-dosing period, with at least a 75% decrease from baseline.
  • Patients reported a dramatic reduction in the daily instances of feeling out of control around their eating habits – with an average reduction of 81.6% in the four weeks after treatment! Even more impressive, 4 out of 5 patients reported a reduction of more than 70%.

Patients treated with TRP-8802 for compulsion-related disorders showed remarkable improvement in their anxiety and depression levels, according to an analysis of the Hospital Anxiety and Depression Scale (HADS) scores. The observed behavioral improvements align closely with those described in other studies on psilocybin as a therapeutic intervention. Moreover, no drug-related adverse events were reported during the four-week period following dosing of TRP-8802 – a testament to the safety and efficacy of this treatment.

The remarkable findings from the STOP Study at the University of Florida, led by psychologist Dr. Jesse Dallery, are an incredibly promising sign for individuals suffering from binge eating, anxiety, and depression. In just one dose of psilocybin in combination with therapy, participants experienced dramatic improvements in all three areas, far surpassing what would typically be seen after a much longer course of evidence-based therapy. These results are a highly positive indication of the potential for psilocybin to be a successful treatment for binge eating and other indicators of quality of life.

Tryp’s CEO, Dr. Jim Gilligan, expressed his enthusiasm for the promising interim analysis results of BED as a viable target for psychedelic-assisted psychotherapy utilizing the company’s proprietary IV formulation of psilocin, TRP-8803. The formulation drastically reduces the time to onset of the psychedelic state, allows for greater control of the depth and duration of the experience, and shortens the overall intervention to a commercially feasible timeframe. With these positive results, Tryp intends to explore the use of TRP-8802 for indications such as BED, fibromyalgia and irritable bowel syndrome, in partnership with leading academic institutions.

Join Tryp Therapeutics on Monday, January 9th at 11am PT to gain insight into the exciting interim data they will be presenting at Biotech Showcase in San Francisco! Don’t miss this incredible opportunity to learn more about the progress of this revolutionary project.

About Binge Eating Disorder (BED)

Do you struggle with overeating and feel like you can’t stop? You may be one of the millions of people living with Binge Eating Disorder (BED). Research shows that nearly 30% of people seeking weight loss treatments have signs of BED, with up to 3.5% of females and 2.0% of males developing it at some point in their lives. Unfortunately, treatments for BED have so far been unsuccessful.

About Tryp Therapeutics

Tryp Therapeutics is a clinical-stage biotechnology company on the cutting edge of medical innovation. They are developing proprietary, novel formulations of psilocin to treat diseases with unmet medical needs. Their lead program, TRP-8803, is a unique IV-infused psilocin formulation that not only reduces the onset time of the psychedelic state, but also controls the depth and duration of the psychedelic experience, making it a commercially viable option. Tryp is currently conducting Phase 2a clinical trials for the treatment of Binge Eating Disorder at the University of Florida and fibromyalgia at the University of Michigan, utilizing TRP-8802 to demonstrate efficacy. With the potential to further improve efficacy, safety, and patient experience, TRP-8803 is poised to revolutionize the treatment of these conditions.

Forward-Looking Information

This news release contains information that could be perceived as forward-looking. It may include phrases such as “plans”, “targets”, “expects” and “does not expect”, as well as words such as “may”, “could”, “would”, “might”, “will” and “will be taken”, which all point to potential future events. These statements are not guarantees of future events, but rather expectations, estimates and projections about what may happen.

Tryp is committed to providing the most accurate forward-looking information available, but there are risks, uncertainties and assumptions that could cause actual results to differ from the projections. To help mitigate these risks, Tryp encourages readers to thoroughly review the Risk Factors section of its final prospectus. While Tryp can’t guarantee the accuracy of its forward-looking statements, it is dedicated to providing the most up-to-date information and will update or alter statements as necessary.

Leave a Comment